A5009747172- SARS-CoV-2 and COVID-19 Research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- vaccines and immunoinformatics approaches
- Cancer Immunotherapy and Biomarkers
- Cell death mechanisms and regulation
- Immune Cell Function and Interaction
- interferon and immune responses
- RNA Interference and Gene Delivery
- Cytomegalovirus and herpesvirus research
- Animal Virus Infections Studies
- Nanowire Synthesis and Applications
- Viral gastroenteritis research and epidemiology
- Advanced Biosensing Techniques and Applications
- Bacillus and Francisella bacterial research
- Cancer Cells and Metastasis
- Cell Adhesion Molecules Research
- Viral Infectious Diseases and Gene Expression in Insects
- Complement system in diseases
- Adenosine and Purinergic Signaling
- Hepatitis B Virus Studies
Chongqing Medical University
2020-2025
Harbin Medical University
2010-2023
University of Toyama
2007-2022
New Technology (Israel)
2007
Tokyo University of Science
2002-2004
The University of Tokyo
2002
The emergence of the SARS-CoV-2 Omicron variant is dominant in many countries worldwide. high number spike mutations responsible for broad immune evasion from existing vaccines and antibody drugs. To understand this, we first present cryo-electron microscopy structure ACE2-bound spike. Comparison to previous structures explains how escapes these therapeutics. Secondly, report Omicron, Delta, wild-type spikes bound a patient-derived Fab fragment (510A5), which provides direct evidence where...
The SARS-CoV-2 Omicron variant of concern (VoC) and its sublineages contain 31-36 mutations in spike escape neutralization by most therapeutic antibodies. In a pseudovirus assay, 66 the nearly 400 candidate therapeutics Coronavirus Immunotherapeutic Consortium (CoVIC) panel neutralize multiple sublineages. Among natural immunoglobulin Gs (IgGs), especially those receptor-binding domain (RBD)-2 epitope community, all neutralizers recognize bivalently, with both antigen-binding fragments...
T cell receptor (TCR)-engineered cells targeting neoantigens originated from mutations in KRAS gene have demonstrated promising outcomes clinical trials against solid tumors. However, the challenge lies developing tumor-specific TCRs that avoid cross-reactivity with self-antigens to minimize possibility of severe toxicities. Current research efforts been put towards strategies eliminate TCR off-target recognition. Naive repertoire was used for screening KRASG12D-reactive TCRs. Specific were...
Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase possibility of immune escape, challenging present COVID-19 prophylaxis and clinical interventions. Here, 3 receptor binding domain (RBD) specific monoclonal antibodies (mAbs), 58G6, 510A5 13G9, with high neutralizing potency blocking authentic virus display remarkable efficacy against B.1.351 virus. Surprisingly, structural analysis has revealed that 58G6 13G9 both recognize steric region S470-495 on RBD, overlapping...
Chemokine (C-C motif) receptor 8 (CCR8) is a chemokine selectively expressed on tumor-infiltrating regulatory T cells (Tregs). Strong immunosuppression mediated by CCR8
Adoptive immunotherapy using CAR-T cells is a promising curative treatment strategy for hematological malignancies. Current manufacture of clinical-grade based on lentiviral/retrovirus transfection T followed by anti-CD3/CD28 activation supplemented with IL-2 has been associated low efficiency and usually the use terminally differentiated effector cells. Thus, improving quality quantity are essential optimizing cell preparation. In our study, we focus role IL-21 in γ c cytokine conditions We...
Despite the growing knowledge of T cell responses in COVID-19 patients, there is a lack detailed characterizations for cell-antigen interactions and functions. Here, with predicted peptide library from SARS-CoV-2 S N proteins, we found that specific CD8+ were identified over 75% convalescent patients (15/20) an epitope protein, N361-369 (KTFPPTEPK), was most dominant our selected library. Importantly, discovered 2 N361-369-specific receptors (TCRs) high functional avidity independent CD8...
After the pandemic of COVID-19, neutralizing antibodies (NAbs) against SARS-CoV-2 have been developed for prophylactic and therapeutic purposes. However, few methodologies are described in detail on how to rapidly efficiently generate effective NAbs SARS-CoV-2. Here, we integrated optimized a strategically screening method NAbs, which has enabled us obtain receptor-binding domain (RBD) specific within 6 days, followed by additional 9 days antibody production function analysis. Using this...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still rapidly spreading worldwide. Many drugs and vaccines have been approved for clinical use show efficacy in the treatment prevention of SARS-CoV-2 infections. However, emergence variants concern (VOCs), such as Delta (B.1.617.2) recently emerged Omicron (B.1.1.529), has seriously challenged application current therapeutics. Therefore, there a pressing need identification new broad-spectrum antivirals. Here, we...
<title>Abstract</title> <bold>Background</bold> Public neoantigens, including KRAS, TP53, and PIK3CA mutations, which are shared across various tumor types, have demonstrated significant immunogenicity offer great promise for cancer immunotherapy. Clinical trials targeting these public neoantigens yielded encouraging results, regression prolonged relapse-free survival. This study evaluates the HLA binding properties of T cell epitopes derived from to identify optimal target, further develops...
Abstract The authors previously developed a cell‐microarray system that effectively detects antigen‐specific B‐cells by monitoring intracellular Ca 2+ at single cell levels. Here they present novel method to detect using system. To B‐cells, arrayed live lymphocytes on chip, stained cells with fluorescence‐labeled nonspecific proteins, and analyzed them fluorescence scanner protein binding B‐cells. They then antigen the scanner. Cells specific antigen, but not were determined as harvested....
ABSTRACT SARS-CoV-2 Spike-specific antibodies contribute the majority of neutralizing activity in most convalescent human sera. Two variants, N501Y.V1 (also known as B.1.1.7 lineage or VOC-202012/01) and N501Y.V2 (B.1.351 lineage), reported from United Kingdom South Africa, contain several mutations receptor binding domain Spike are particular concern. To address infectivity neutralization escape phenotypes potentially caused by these mutations, we used pseudovirus system to compare viral...
Adoptive immunotherapy with CMV-specific T cells (CMV-VSTs) has shown favorable efficacy and minimal adverse effects in clinical settings, serving as prophylaxis, preemptive and/or curative treatment for the restoration of immunity patients after allogeneic hematopoietic stem cell transplantation. The establishment a CMV-VST bank enables prompt use CMV-VSTs off-the-shelf therapeutics. can be generated through culture or immunomagnetic selection based on IFN-γ secretion multimer technology....
Antigen-specific rabbit monoclonal antibodies (RaMoAbs) are useful due to their high specificity and affinity, the establishment of a comprehensive rapid RaMoAb generation system has been highly anticipated. Here, we present novel using immunospot array assay on chip (ISAAC) technology in which detect retrieve antigen-specific antibody-secreting cells from peripheral blood lymphocytes antigen-immunized rabbits produce RaMoAbs with 10–12 M affinity within time period only 7 days. We have used...
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Spike protein that mediates entry into host cells a major target for COVID-19 vaccines and antibody therapeutics. However, multiple variants of SARS-CoV-2 have emerged, which may potentially compromise vaccine effectiveness. Using pseudovirus-based assay, we evaluated cell mediated the viral B.1.617 B.1.1.7 variants. We also compared neutralization ability monoclonal antibodies...
Facing the imminent need for vaccine candidates with cross-protection against globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants, we present a conserved antigenic peptide RBD9.1 both T-cell and B-cell epitopes. can be recognized by disease 2019 (COVID-19) convalescent serum, particularly those high neutralizing potency. Immunization successfully induce production of receptor-binding domain (RBD)-specific antibodies in Balb/c mice. Importantly, immunized...